Multi-targeting and identification of synergistic activities to overcome therapy resistance in ALL (B06)

• Subject Area: Hematology, Oncology
• Term: from 2012 to 2024
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 217328187

Despite high cure rates, therapy resistance is a major clinical challenge in the treatment of pediatric acute lymphoblastic leukemia (ALL). This project aims at identifying vulnerabilities and cooperative activities of single compounds and combinations of classical chemotherapeutics and agents targeting different cellular pathways. Pharmaco-profiles will be analyzed in a series of characterized patient-derived xenograft ALL samples established in our NOD/SCID/huALL system. Identified combinations showing synthetic lethality will be further pre-clinically evaluated in phase-II-like studies in our xenograft system.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 1074: Experimental Models and Clinical Translation in Leukemia
• Applicant Institution: Universität Ulm
• Project Heads: Professor Dr. Klaus-Michael Debatin; Professor Dr. Lüder Hinrich Meyer